GlycoMimetics Entered Into Project Agreement With Patheon Manufacturing Services, Part Of Thermo Fisher Scientific; Patheon Will Manufacture, Supply Co With Drug Candidate, Uproleselan, For Commercial Sale Should Co Receive Marketing Approval From FDA
Portfolio Pulse from Benzinga Newsdesk
GlycoMimetics has signed a project agreement with Patheon Manufacturing Services, a part of Thermo Fisher Scientific. Under this agreement, Patheon will manufacture and supply GlycoMimetics with its drug candidate, Uproleselan, for commercial sale pending FDA approval, as disclosed in an SEC 8K filing.
January 02, 2024 | 9:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GlycoMimetics has entered into an agreement with Patheon for the manufacturing of its drug candidate Uproleselan, which is awaiting FDA approval for commercial sale.
The agreement with Patheon is a significant step for GlycoMimetics, as it secures a manufacturing partner for Uproleselan, which is crucial for its commercialization strategy. This news is likely to be viewed positively by investors as it demonstrates progress towards market entry, assuming FDA approval is granted. The importance is high as manufacturing is a critical component of drug commercialization, but not at the maximum since FDA approval is still pending.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Thermo Fisher Scientific's Patheon division will be responsible for the manufacturing and supply of GlycoMimetics' drug candidate Uproleselan, should it receive FDA approval for commercial sale.
The contract with GlycoMimetics could expand Thermo Fisher's Patheon service portfolio and revenue, assuming Uproleselan is approved by the FDA. The impact is positive as it represents business growth for Thermo Fisher, but the importance is moderate because Thermo Fisher is a large company with a diversified portfolio, and this contract is just one of many potential revenue streams.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70